aTyr Pharma, Inc.

1.94 USD
+0.02 (+1.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

aTyr Pharma, Inc. stock is up 21.25% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 March’s closed higher than February. 100% of analysts rate it a buy.

About aTyr Pharma, Inc.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.